Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.
KIRhub 2.0· v2
Ependymoma Hub
V1V2
Sign in
← Cases

Fedratinib

73fe6d0b-d73e-521f-9c0b-8664e95e3974 · FDA Approved · targets JAK2

Fedratinib

MeasuredReference

Fedratinib targets RET, JAK2, FLT3. Strongest hallmark effect: tumor promoting inflammation.

Primary targets

RETJAK2FLT3ZIPK_DAPK3DAPK1

Top hallmarks

  • tumor promoting inflammation5.8k
  • evading apoptosis4.3k
  • proliferation4.3k

Top pathways disrupted

  • apical junction10.1k
  • pi3k akt mtor signaling10.1k
  • allograft rejection10.0k

Resistance landscape — Fedratinib

MeasuredReference

10 known oncogenic variants exist on Fedratinib's top targets — see detail for inhibition impact.

Open in new tab